Evidence map›Paper›PMID 42195046›Full record

ArticleGenes2026

The Impact of

Sylwia Szeląg-Pieniek, Joanna Kucak, Damian Malinowski, Stefan Oswald, Marek Droździk, Mateusz Kurzawski

Abstract read
In one paragraph

Article in Genes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sylwia Szeląg-PieniekDepartment of Experimental and Clinical Pharmacology, Pomeranian Medical University, Al. Powstańców Wlkp. 72, 70-111 Szczecin, Poland.
Joanna KucakIndependent Pharmacodynamics Laboratory, Pomeranian Medical University, pl. Polskiego Czerwonego Krzyża 1, 71-244 Szczecin, Poland.
Damian MalinowskiDepartment of Pharmacokinetics and Monitored Therapy, Pomeranian Medical University, Al. Powstańców Wlkp. 72, 70-111 Szczecin, Poland.ORCID 0000-0001-8393-9627
Stefan OswaldInstitute of Pharmacology and Toxicology, Rostock University Medical Center, 18057 Rostock, Germany.ORCID 0000-0001-6269-4368
Marek DroździkDepartment of Experimental and Clinical Pharmacology, Pomeranian Medical University, Al. Powstańców Wlkp. 72, 70-111 Szczecin, Poland.ORCID 0000-0002-6191-7168
Mateusz KurzawskiIndependent Pharmacodynamics Laboratory, Pomeranian Medical University, pl. Polskiego Czerwonego Krzyża 1, 71-244 Szczecin, Poland.ORCID 0000-0002-4293-7788

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGlucuronidation is a major phase II biotransformation reaction responsible for the inactivation and elimination of endogenous compounds and pharmaceuticals. This process is catalyzed by enzymes belonging to the UDP-glucuronosyltransferase (UGT) family, among which UGT1A1 is the most extensively studied. UGT1A1 plays a critical role in the metabolism of numerous drugs and is essential for bilirubin glucuronidation. Due to this specific function, it has significant clinical relevance, as impaired enzyme activity resulting from genetic polymorphisms or mutations can lead to the accumulation of unconjugated bilirubin in the bloodstream. This study aimed to evaluate the association between the

methodsLiver tissues were obtained from patients with various liver pathologies and the control group consisted of tissues showing no pathological symptoms. A total of 143 patients were included in the study. Pyrosequencing was used to analyze PCR products for the

resultsIn both the control and study groups,

conclusionsThe

Indexed as

GlucuronosyltransferaseLiverLiver DiseasesAdultAgedAllelesFemaleGenotypeHumansMaleMiddle AgedPolymorphism, GeneticPromoter Regions, GeneticRNA, MessengerUGT1A1 EnzymeGlucuronosyltransferaseRNA, MessengerUGT1A1 Enzymedrug metabolismGilbert’s syndromeglucuronidationliver pathologyUDP-glucuronosyltransferase

Identifiers

PMID42195046
PMCPMC13205437

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.